A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

NCT03800134 PHASE3 ACTIVE_NOT_RECRUITING

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

Details

Lead sponsor	AstraZeneca
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	825
Start date	Thu Dec 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Durvalumab
• Placebo
• Carboplatin
• Cisplatin
• Pemetrexed
• Paclitaxel
• Gemcitabine
• Surgery

Countries

Italy, Japan, Taiwan, Vietnam, Poland, South Korea, Philippines, Costa Rica, Netherlands, Russia, Belgium, Mexico, Thailand, Bulgaria, United States, France, Austria, Chile, Hungary, Argentina, Canada, Romania, Brazil, Spain, Peru, Germany, China, India